Abstract Number: 2903 • 2018 ACR/ARHP Annual Meeting
Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
Background/Purpose: Defining the precise CD4+ T cell subsets that are dysregulated in RA patients is critical to deciphering pathogenesis. Here we present Mixed effects modeling…Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…Abstract Number: 2905 • 2018 ACR/ARHP Annual Meeting
Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA
Background/Purpose: EULAR recommendations suggest diagnostic imaging in all GCA suspects. Vascular ultrasound (US) is cheap, readily available and the recommended first line examination in cranial…Abstract Number: 2906 • 2018 ACR/ARHP Annual Meeting
Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy
Background/Purpose: Musculoskeletal ultrasound is increasingly being used as a tool to assess inflammatory burden in rheumatoid arthritis (RA). Ultrasound-based outcome measures include power Doppler (PD)…Abstract Number: 2907 • 2018 ACR/ARHP Annual Meeting
Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Background/Purpose: In the treatment…Abstract Number: 2908 • 2018 ACR/ARHP Annual Meeting
Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients
Background/Purpose: To evaluate the agreement between ultrasound (US), whole body magnetic resonance imaging (WBMRI) and clinical assessment of joint inflammation and enthesitis in rheumatoid arthritis…Abstract Number: 2909 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Prognostic Value of Ultrasound Compared with Plain Radiography in Knee Osteoarthritis
Background/Purpose: Plain radiography of knee osteoarthritis (OA) has inherent diagnostic and prognostic limitations, especially in early disease. Ultrasound (US) examination sheds light on disease activity…Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting
Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…Abstract Number: 2912 • 2018 ACR/ARHP Annual Meeting
Lupus Flare Activity from the Patient Perspective
Background/Purpose: Lupus patients may experience flares in disease activity that require rapid management. This study describes the experience, identification, and management of a flare from…Abstract Number: 2913 • 2018 ACR/ARHP Annual Meeting
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An OMERACT ReportBackground/Purpose: The OMERACT Myositis special interest…Abstract Number: 2914 • 2018 ACR/ARHP Annual Meeting
Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis
Background/Purpose: PROMIS (Patient-Reported Outcomes Measurement Information System) measures have not been tested in psoriatic arthritis (PsA). We examined the reliability, validity and responsiveness of the…Abstract Number: 2915 • 2018 ACR/ARHP Annual Meeting
Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
Background/Purpose: Advances in reality mining combined with the pervasive use of smart phones have shown measurable changes in phone behavior due to changes in health.…Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting
New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…Abstract Number: 2917 • 2018 ACR/ARHP Annual Meeting
Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Canakinumab (CAN), a monoclonal anti-interleukin (IL)-1β antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). CAN-treated patients with SJIA showed a…